JPRN-UMIN000002154已完成2 期
Randomized phase II study comparing 2nd line therapy for gemcitabine-refractry advanced pancreatic cancer. - Randomized phase II study comparing 2nd line therapy for gemcitabine-refractry advanced pancreatic cancer.
Osaka Medical Center for Cancer and Cardiovascular Diseases Department of Medical Oncology Pancreatic cancer study Group0 个研究点目标入组 80 人开始时间: 2009年7月2日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Lung fibrosis or intestinal pneumoni, and anamnesis or imaging findings. 2) Severe infection. 3) Severe complication. (heart failure, angina pectoris, arrhythmia, diabetes , intestines paralysis, ileus, myocardial infarction within 6 months after the onset.) 4) Pregnant or lactation women, or women with known or suspected pregnancy and men who want let to pregnancy. 5) Watery diarrhea. 6) Jaundice. 7) Uncontrolled pleural or abdominal effusion. 8) Severe drug hypersensitivity. 9) History of other active malignancy. 10) Severe mental illness 11) Patients who are judged inappropriate for the entry into the study by the investigater.
研究者
相似试验
进行中（未招募）
1 期
Randomised study for second line treatment with nal-IRI and S1 in pancreatic cancer.pancreatic cancerEUCTR2017-004675-31-NLAcademic Medical Center120
进行中（未招募）
2 期
A randomized phase II study of second line treatment with liposomal irinotecan and S1 versus liposomal irinotecan and 5-fluorouracil in patients with metastatic pancreatic cancer who failed on first line gemcitabine-based chemotherapy2023-509463-24-01Amsterdam UMC146
进行中（未招募）
1 期
Randomised study for second line treatment with nal-IRI and S1 in pancreatic cancer.pancreatic cancerEUCTR2017-004675-31-ATAcademic Medical Center120
进行中（未招募）
1 期
Phase II study of treatment with liposomal and S1 irinotecan versus liposomal and 5-fluorouracil irinotecan in patients with metastatic pancreatic cancer who did not achieve results with gemcitabine first-line chemotherapyMedDRA version: 21.0Level: LLTClassification code 10033599Term: Pancreatic adenocarcinoma metastaticSystem Organ Class: 100000004864pancreatic cancerEUCTR2017-004675-31-ITACADEMIC MEDICAL CENTRE AMSTERDAM90
招募中
2 期
A randomized Phase II study of second line treatment with liposomal irinotecan and S1 versus liposomal irinotecan and 5-fluorouracil in patients with metastatic pancreatic cancer who failed on first line gemcitabine-based chemotherapypancreatic cancer10017991NL-OMON55645Academisch Medisch Centrum25